Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 37, 2013, Pages 15001-15006

  Fuller, Michael J ^a,h   Callendret, Benoit ^a   Zhu, Baogong ^b   Freeman, Gordon J ^b   Hasselschwert, Dana L ^c   Satterfield, William ^d   Sharpe, Arlene H ^b   Dustin, Lynn B ^e   Rice, Charles M ^e   Grakoui, Arash ^f   Ahmed, Rafi ^f   Walker, Christopher M ^a,g  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF LOUISIANA AT LAFAYETTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

^f EMORY UNIVERSITY   (United States)

^g THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CHIMPANZEE; CONTROLLED STUDY; DRUG SAFETY; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIREMIA; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOTHERAPY; PAN TROGLODYTES; PROGRAMMED CELL DEATH 1 RECEPTOR; VIREMIA; VIRUS REPLICATION;

EID: 84883746616     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1312772110     Document Type: Article

References (36)

1. Odorizzi PM, Wherry EJ (2012) Inhibitory receptors on lymphocytes: Insights from infections. J Immunol 188(7):2957-2965.
2. Topalian SL, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454.
3. Brahmer JR, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455-2465.
4. Barber DL, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682-687. (Pubitemid 43237609)
5. Velu V, et al. (2009) Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458(7235):206-210.
6. Dyavar Shetty R, et al. (2012) PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 122(5):1712-1716.
7. Rehermann B (2009) Hepatitis C virus versus innate and adaptive immune responses: A tale of coevolution and coexistence. J Clin Invest 119(7):1745-1754.
8. Chisari FV, Isogawa M, Wieland SF (2010) Pathogenesis of hepatitis B virus infection. Pathol Biol 58(4):258-266.
9. Schurich A, et al. (2011) Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53(5):1494-1503.
10. Racanelli V, Leone P, Grakoui A (2011) A spatial view of the CD8+ T-cell response: The case of HCV. Rev Med Virol 21(6):347-357.
11. Klenerman P, Thimme R (2012) T cell responses in hepatitis C: The good, the bad and the unconventional. Gut 61(8):1226-1234.
12. Raziorrouh B, et al. (2011) Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection. Gastroenterology 141(4):1422-1431.
13. Bowen DG, Walker CM (2005) Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 201(11):1709-1714. (Pubitemid 41002889)
14. Walker CM (2010) Adaptive immunity to the hepatitis C virus. Adv Virus Res 78:43-86.
15. Rollier CS, et al. (2007) Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 45(3):602-613. (Pubitemid 46450611)
16. Bowen DG, et al. (2008) Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J Virol 82(10):5109-5114. (Pubitemid 351657073)
17. Kolykhalov AA, et al. (1997) Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277(5325):570-574. (Pubitemid 27369006)
18. Gottwein JM, et al. (2010) Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): Genetic analyses and in vivo pathogenesis studies. J Virol 84(10):5277-5293.
19. Thimme R, et al. (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194(10):1395-1406. (Pubitemid 33081515)
20. Thimme R, et al. (2002) Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 99(24):15661-15668. (Pubitemid 35403988)
21. Jo J, et al. (2009) Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 136(4):1391-1401.
22. Sant AJ, McMichael A (2012) Revealing the role of CD4(+) T cells in viral immunity. J Exp Med 209(8):1391-1395.
23. Grakoui A, et al. (2003) HCV persistence and immune evasion in the absence of memory T cell help. Science 302(5645):659-662. (Pubitemid 37310924)
24. Erickson AL, et al. (2001) The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15(6):883-895. (Pubitemid 34075370)
25. Erickson AL, et al. (1993) Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol 151(8):4189-4199. (Pubitemid 23298752)
26. Timm J, et al. (2004) CD8 epitope escape and reversion in acute HCV infection. J Exp Med 200(12):1593-1604. (Pubitemid 40094183)
27. Cox AL, et al. (2005) Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 201(11):1741-1752. (Pubitemid 41002893)
28. Ray SC, et al. (2005) Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med 201(11):1753-1759. (Pubitemid 41002894)
29. Tester I, et al. (2005) Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med 201(11):1725-1731. (Pubitemid 41002891)
30. Ha SJ, et al. (2008) Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 205(3):543-555.
31. Deeks SG, et al.; International AIDS Society Scientific Working Group on HIV Cure (2012) Towards an HIV cure: A global scientific strategy. Nat Rev Immunol 12(8):607-614.
32. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ (2006) Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 30(7):802-810. (Pubitemid 44264969)
33. Zhu B, Cai G, Hall EO, Freeman GJ (2007) In-fusion assembly: Seamless engineering of multidomain fusion proteins, modular vectors, and mutations. Biotechniques 43(3):354-359. (Pubitemid 47417276)
34. Naito M, et al. (2013) CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother 62(2):347-357.
35. Brown JA, et al. (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170(3):1257-1266. (Pubitemid 36139491)
36. Latchman Y, et al. (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261-268. (Pubitemid 33706004)